汇宇制药股价跌5.11%，大成基金旗下1只基金重仓，持有43.15万股浮亏损失49.19万元

Group 1 - The core viewpoint of the news is that Huili Pharmaceutical's stock has experienced a significant decline, with a 5.11% drop on September 29, leading to a cumulative decline of 11.16% over three consecutive days [1][2] - Huili Pharmaceutical, established on October 12, 2010, and listed on October 26, 2021, specializes in the research, production, and sales of oncology drugs and complex injectable drugs [1] - The company's main revenue sources are drug sales (97.27%), technical services (1.66%), and other income (1.07%) [1] Group 2 - Dachen Fund has a significant holding in Huili Pharmaceutical, with its Dachen Medical Health Stock A fund holding 431,500 shares, representing 4.07% of the fund's net value [2] - The fund has incurred a floating loss of approximately 491,900 yuan today and a total floating loss of 1,208,100 yuan during the three-day decline [2] - Dachen Medical Health Stock A fund was established on September 16, 2021, with a current size of 153 million yuan and has achieved a year-to-date return of 33.89% [2]